Physician profile
Sonu Singh
NPI 1366477424
$2,393.71
in general payments reported to CMS, 2019-2025
20 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $87.69 · 2021: $329 · 2022: $437 · 2023: $429 · 2024: $396 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.48 |
| Education | $106.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $401.06 | 2019-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $327.08 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $218.46 | 2021-2025 | Filspari |
| Vifor Pharma, INC. | $200.25 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $191.13 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $182.99 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $170.10 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $133.41 | 2021-2024 | Lupkynis |
| Amgen INC. | $133.38 | 2022 | |
| Ardelyx, INC. | $82.93 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $69.76 | 2022-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $51.15 | 2019 | |
| Alnylam Pharmaceuticals INC. | $35.46 | 2025 | Amvuttra |
| Novo Nordisk INC | $34.60 | 2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $33.79 | 2023-2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $33.28 | 2019 | |
| Calliditas Therapeutics US INC. | $32.25 | 2022-2024 | |
| Glaxosmithkline, LLC. | $24.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.60 | 2025 | |
| Daiichi Sankyo INC. | $16.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonu Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.